Potential 20-Week Faricimab Dosing in Wet Age-Related Macular Degeneration
Patients with nAMD in TENAYA/LUCERNE always on extended faricimab dosing (≥12-weeks) achieved robust disease control throughout 2 years. Additionally, 56% of patients could have potentially extended to every-20-week dosing had the protocol allowed.
Authors
- Nikolas London (ORCID: https://orcid.org/0000-0001-9809-6108)
- Aachal Kotecha (ORCID: https://orcid.org/0000-0003-4989-9216)
- Hill LF
- PJ Patel
- Varun Chaudhary
- Aude Ambresin
- Richard Gale
- Adrian Koh
- Anna C.S. Tan
Institutions
- Roche (Switzerland) (CH)
- SIB Swiss Institute of Bioinformatics (CH)
- Moorfields Eye Hospital NHS Foundation Trust (GB)
- Singapore National Eye Center (SG)
- California Retina Consultants (US)
- Medical Center Ophthalmology Associates (US)
- Eye & Retina Surgeons (SG)
- Roche (United Kingdom) (GB)
- York Teaching Hospital NHS Foundation Trust (GB)
- University College London (GB)
- Hull York Medical School (GB)
- McMaster University (CA)
Publication Details
- Journal
- Ophthalmology Retina
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1016/j.oret.2026.02.001
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00